Viking Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Viking Therapeutics, Inc.
Inventiva’s pan-PPAR agonist and Terns’ combination strategy are targeting the NASH treatment paradigm after expected approval of Madrigal’s resmetirom. Viking is hoping to prove a better THRβ drug profile than Madrigal.
TERN-501 monotherapy looks serviceable in a mid-stage NASH trial, but others are ahead. Perhaps partnership is the way forward.
While Intercept is calling it quits in NASH with its FXR agonist obeticholic acid following a second complete response letter, other companies are staying the course with Phase II molecules in the class.
While progress in NASH has been slow for years, two dual GLP-1/GR agonists from rivals Merck & Co and Altimmune are showing mid-stage promise.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.